• metastatic-recurrent HNSCC (mHNSCC)
• mHNSCC - (neo)adjuvant (NA)
• mHNSCC - 1st line (L1)
• mHNSCC - L1 - all population 2
• mHNSCC - L1 - PDL1 positive 4
• mHNSCC - 2nd line (L2)
• mHNSCC - L2 - all population 4
• mHNSCC - L2 - PDL1 negative 2
• mHNSCC - L2 - PDL1 positive 1
• hepatocell cancer (HCC)

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab plus bevacizumab
• nivolumab based treatment
• nivolumab alone
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab plus lenvatinib
• sintilimab based treatment
• sintilimab

• versus all
• vs non active control
• vs placebo
• vs VEGF(R) inhibitor
• vs lenvatinib
• vs sorafenib

  All patients

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

hepatocell cancer (HCC), nivolumab based treatment vs. all, meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;